CILAZAPRIL 2.5 MG
CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 2.5 MG · DIN 02345226 · COBALT PHARMACEUTICALS COMPANY
Health Canada status: CANCELLED PRE MARKET
What is CILAZAPRIL?
CILAZAPRIL 2.5 MG contains CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02345226, held by COBALT PHARMACEUTICALS COMPANY, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 01-Sep-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02345226 |
|---|---|
| Brand name | CILAZAPRIL |
| Generic / active ingredient | CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 2.5 MG |
| Manufacturer | COBALT PHARMACEUTICALS COMPANY |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA08 CILAZAPRIL |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 01-Sep-2017 |
What can be used instead?
Other Canadian products sharing ATC code C09AA08 CILAZAPRIL. 6 of 33 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CILAZAPRIL | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02291142 |
| APO-CILAZAPRIL | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02291150 |
| INHIBACE | 5 MG | TABLET | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 01911481 |
| MYLAN-CILAZAPRIL | 1 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02283778 |
| MYLAN-CILAZAPRIL | 2.5 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02283786 |
| MYLAN-CILAZAPRIL | 5.0 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02283794 |
| APO-CILAZAPRIL | 1 MG | TABLET | APOTEX INC | DORMANT | DIN 02291134 |
| CILAZAPRIL | 1 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02350963 |
| CILAZAPRIL | 1.0 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED PRE MARKET | DIN 02345218 |
| CILAZAPRIL | 2.5 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02350971 |
Who else supplies CILAZAPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CILAZAPRIL appears in 16 registered pack listings across 7 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.